Skip to main content
Premium Trial:

Request an Annual Quote

Analyte Health, IQuity Ink Deal to Expand Access to Dx Tests

NEW YORK (360Dx) – Analyte Health said Thursday it has reached a deal to provide certain patients access to IQuity's diagnostic tests.

Qualified patients will have immediate access to IsolateMS ­– IQuity's test to help clinicians decide whether a patient may have multiple sclerosis – through Analyte's Health Test Express website. The test is based on an RNA analytic process dubbed IQIsolate to confirm suspected autoimmune diagnosis.

Analyte and IQuity expect to make other tests available through the deal, including the IsolateIBS-IBD test for differentiating irritable bowel syndrome from inflammatory bowel disease, and the IsolateFibromyalgia test. The two tests are expected to be available through Health Test Express during the first quarter.

IQuity will run the three tests in its CLIA-certified lab in Nashville, Tennessee.

Financial and other terms of the agreement were not disclosed.

Based in Chicago, Analyte Health aims to provide consumers information about and access to diagnostics through a network of diagnostic service centers, online digital assets, at-home diagnostic kits, and telehealth technologies.

IQuity is a data science firm, leveraging genomics for the detection and monitoring of chronic diseases.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.